Asklepios Klinik Harburg

The trials here

What the 4 trials at this site are about, from their registry records.

Conditions

• Lung cancer4 trials

Phase

• Phase 33 trials
• Phase 41 trial

Status

• Recruiting2 trials
• Active, not recruiting1 trial
• Completed1 trial

Lead sponsor

• Hoffmann-La Roche2 trials
• Eli Lilly and Company1 trial
• Pharmacosmos A/S1 trial

Running trials

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  NCT06890598· Phase 3· Eli Lilly and Company· Source

  Contact: Claas Wesseler (principal investigator)

• Active, not recruiting

  Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

  NCT05874401· Phase 4· Pharmacosmos A/S· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer2 recruiting

Closed trials

• Completed

  A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

  NCT04256421· Phase 3· Hoffmann-La Roche· Source